Core Viewpoint - Ningbo Meinuo Pharmaceutical Co., Ltd. announced that its wholly-owned subsidiary, Ningbo Meinuo TianKang Pharmaceutical Co., Ltd., participated in the national centralized procurement for drugs whose agreements have expired, with ten products including Perindopril tert-butylamine tablets, Clopidogrel hydrogen sulfate tablets, and Empagliflozin tablets expected to be selected for this procurement [1]. Group 1: Proposed Selected Products - The ten proposed selected products are expected to generate a total sales revenue of 71.75 million yuan in the first three quarters of 2025, accounting for 6.4% of the company's total revenue during the same period [1]. - The number of proposed selected products represents 40% of the total number of formulations in the company's formulation segment [1]. Group 2: Impact on the Company - The results of the procurement are expected to be implemented by the end of March 2026, with medical institutions prioritizing the use of the selected drugs during the procurement cycle [1]. - The procurement cycle for the selected drugs will last until December 31, 2028, starting from the actual execution date of the selection results [1].

Core Viewpoint - Meihua announced that its wholly-owned subsidiary, Ningbo Meihua Tiankang Pharmaceutical Co., Ltd., participated in the national centralized procurement for drugs whose agreements have expired, with ten products expected to be selected for this procurement [1] Group 1: Procurement Participation - The selected products include Perindopril tert-butylamine tablets, Clopidogrel hydrogen sulfate tablets, and Empagliflozin tablets among others [1] - The procurement is part of the continuation of the national centralized procurement for drugs from batches 1-8, with results expected to be implemented by the end of March 2026 [1] Group 2: Financial Impact - The total sales for the ten selected products are projected to be 71.75 million yuan for the first three quarters of 2025, accounting for 6.4% of the company's total revenue during the same period [1] - The number of selected products represents 40% of the total products in the formulation segment of the company [1] Group 3: Procurement Cycle - The procurement cycle for the selected drugs will run from the actual execution date of the selection results until December 31, 2028 [1] - Medical institutions will prioritize the use of the selected drugs during the procurement cycle and ensure the completion of the agreed procurement volume [1]

Core Viewpoint - Meinuohua's subsidiary, Ningbo Meinuohua Tiankang Pharmaceutical Co., Ltd., is participating in the national organized procurement for drugs whose agreements have expired, with ten products expected to be selected for this procurement [1] Group 1: Procurement Participation - The company is involved in the bidding for the continuation of procurement for drugs that are part of the first to eighth batches of the national organized procurement agreements that have expired [1] - The expected selected products include Perindopril tert-butylamine tablets, Clopidogrel hydrogen sulfate tablets, and Empagliflozin tablets among others [1] Group 2: Procurement Timeline - The results of the procurement selection are anticipated to be implemented by the end of March 2026 [1] - The procurement cycle for the selected drugs will last from the actual execution date of the selection results until December 31, 2028 [1] Group 3: Procurement Prioritization - During the procurement cycle, medical institutions will prioritize the use of the drugs selected in this continuation procurement and ensure the completion of the agreed procurement volume [1]

Summary of Yandong Biopharmaceuticals Conference Call Company Overview - **Company**: Yandong Biopharmaceuticals - **Date**: August 19, 2025 Key Points Industry and Company Performance - Yandong Biopharmaceuticals reported a revenue of **654 million** yuan in the first half of 2025, a decrease of **2.25%** year-on-year [3] - The net profit attributable to shareholders was **137 million** yuan, down **6.77%** year-on-year, with a non-recurring net profit of **104 million** yuan, a decrease of **8.68%** [3] - The company faced challenges from the **10th batch of national centralized procurement** and intensified industry competition, but maintained operational stability through innovation and efficiency improvements [3] Research and Development (R&D) Investment - R&D investment reached **133 million** yuan, an increase of **8.74%** year-on-year, accounting for **20.25%** of revenue [2][4] - Over **33%** of R&D investment was directed towards innovative drugs, including small molecule drugs and biopharmaceuticals [2][4] - The company is accelerating international business, particularly in the development and certification of nasal spray products [4] Product Pipeline and Sales Performance - In the **anesthesia and analgesia** sector, traditional products like **ibuprofen injection** showed stable growth, while new products like **butorphanol tartrate injection** are experiencing rapid growth [6] - The **cardiovascular** sector saw significant growth in products like **sodium hydrogen clopidogrel tablets** and **bisoprolol amlodipine tablets** [6] - The domestic formulation segment focuses on high-barrier complex formulations, with **21** production approvals granted this year [7] Innovation and Clinical Trials - The innovative drug segment includes several key projects: - **EP9,001A monoclonal antibody injection** completed Phase 1 clinical trials [8] - **YLSH003 ADC** has completed IND application [8] - **EP0,170T** is in Phase 3 clinical trials, targeting cardiovascular diseases [8] - The company is also advancing its **HP001** immune regulator, which shows potential advantages over existing treatments [17][19] Internationalization and Market Expansion - The international business achieved over **10 million** yuan in revenue in the first half of the year, with plans to expand into Southeast Asia and other markets [11] - The nasal spray production line passed FDA inspection, and the company signed a commercialization agreement with **Glenmark** for the naloxone nasal spray [11][14] Financial Outlook and Strategic Initiatives - The company anticipates a challenging year due to the impact of centralized procurement but aims for double-digit growth in revenue and a **20%** increase in profit through strategic initiatives [31] - Yandong plans to maintain R&D investment at over **20%** of revenue, focusing on innovative drugs and biopharmaceuticals [32] - The acquisition of **Chao Yang Pharmaceutical** is expected to positively impact financial results, with a manageable effect on Yandong's financial statements [33] Future Directions - Yandong will continue to focus on accelerating innovative drug development, optimizing resource allocation, and enhancing international market presence [36] - The company aims to leverage its current investments in innovation to drive future growth and maintain a competitive edge in the market [36] Additional Insights - The company is actively pursuing partnerships and collaborations to enhance its product pipeline and market reach [21][24] - Yandong's strategic focus on high-barrier products and innovative therapies positions it well for future growth despite current market challenges [32][34]

Policy Developments - The National Healthcare Security Administration has revised the medical price and procurement credit evaluation system to combat commercial bribery and encourage integrity among pharmaceutical companies [2][3] - The revised system aims to increase the cost of dishonesty for companies and promote compliance, quality improvement, and effective market participation through collective procurement and national negotiations [2][3] Industry Updates - The internal whistleblower reward system for drug and medical device quality safety has been announced, incentivizing individuals who provide clear evidence of violations that lead to administrative penalties or criminal prosecution [4] - A notification has been issued to promote pain relief services during childbirth across various medical institutions, with goals set for 2025 and 2027 to ensure comprehensive service availability [5] Company News - Puluo Pharmaceutical has received approval for the listing application of Succinic Acid Desvenlafaxine, a third-generation antidepressant for treating major depressive disorder [7] - China Pharmaceutical has obtained a drug registration certificate for Sulfhydryl Clopidogrel Tablets, aimed at secondary prevention of atherosclerotic thromboembolic events in specific patient groups [8] - Shanghai Sipurei Pharmaceutical Technology has completed over 200 million RMB in angel round financing, with funds allocated for preclinical and early clinical development [11] - Kelun Pharmaceutical's subsidiary plans to raise approximately 1.943 billion HKD through a share placement to support product development and operational needs [12] - Merck KGaA has entered a strategic partnership with Zai Lab to commercialize a recombinant human thyroid-stimulating hormone in mainland China [14] - China National Pharmaceutical Group has established a technology innovation research institute with a registered capital of 1 billion RMB, focusing on various research and development activities [15] Management Changes - Tongrentang Technology announced the resignation of its chairman and general manager due to work changes, indicating potential shifts in company leadership [17]

Core Viewpoint - China National Pharmaceutical Group's subsidiary, Tianfang Pharmaceutical, has received a drug registration certificate for Clopidogrel Hydrogen Sulfate Tablets, which is expected to enhance the company's cardiovascular medication product line and provide valuable experience for future generic drug development [1][6]. Group 1: Drug Registration Information - The drug name is Clopidogrel Hydrogen Sulfate Tablets, with a specification of 75mg [1]. - The registration application was accepted by the National Medical Products Administration (NMPA) in January 2024 [3]. - The total investment in the drug development has reached approximately 19.54 million RMB (about 2.95 million USD) [4]. Group 2: Market Situation - As of the announcement date, 21 other companies, including Shijiazhuang Yiling Pharmaceutical, Shenzhen Mindray Bio-Medical Electronics, and Zhejiang Jingxin Pharmaceutical, have also obtained production licenses for this drug [5]. - Clopidogrel Hydrogen Sulfate Tablets are classified as a Category B drug under the medical insurance system, with total domestic sales of approximately 4.924 billion RMB (about 0.74 billion USD) in 2023 and projected sales of about 5.376 billion RMB (about 0.81 billion USD) in 2024 [5].